医药稳健科研股策略:年化收益率（25.27%）
本策略精选医药生物行业中研发投入高、净利润快速增长、估值合理的优质股票。通过量化财务指标，筛选出具备持续成长潜力的标的，并定期轮动调仓，力求在医药行业中获取稳健收益。
概要
核心指标
- 累计收益率: 45.44%
- 年化收益率: 25.27%
- 基准收益率: 3.07%
- 阿尔法: 0.26
- 夏普比率: 0.84
- 最大回撤: 22.06%
源码
查看AI策略代码
绩效
持仓详情
|
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
|---|---|---|---|---|---|---|---|
| 2025-06-06 | 亚宝药业(600351.SH) | 5.8436674002757 | 78830 | 23 | 6.25 | 492687.5 | 32031.2/6.953% |
| 2025-06-06 | 国药现代(600420.SH) | 10.299906 | 45000 | 23 | 10.75 | 483750 | 20254.23/4.37% |
| 2025-06-06 | 浙江医药(600216.SH) | 13.990753582271 | 32200 | 53 | 14.83 | 477526 | 27023.73/5.999% |
| 2025-06-05 | 亚宝药业(600351.SH) | 5.8436674002757 | 78830 | 22 | 6.14 | 484016.2 | 23359.9/5.071% |
| 2025-06-05 | 国药现代(600420.SH) | 10.299906 | 45000 | 22 | 10.75 | 483750 | 20254.23/4.37% |
| 2025-06-05 | 浙江医药(600216.SH) | 13.990753582271 | 32200 | 52 | 15.04 | 484288 | 33785.73/7.5% |
| 2025-06-04 | 亚宝药业(600351.SH) | 5.8436674002757 | 78830 | 21 | 6.23 | 491110.9 | 30454.6/6.611% |
| 2025-06-04 | 国药现代(600420.SH) | 10.299906 | 45000 | 21 | 10.88 | 489600 | 26104.23/5.632% |
| 2025-06-04 | 浙江医药(600216.SH) | 13.990753582271 | 32200 | 51 | 15.04 | 484288 | 33785.73/7.5% |
| 2025-06-03 | 亚宝药业(600351.SH) | 5.8322077565976 | 76730 | 20 | 6.2 | 475726 | 28220.7/6.306% |
交易详情
| 2025-06-04 | 浙江医药(600216.SH) | 卖 | -1500 | 15.12 | -22680 | ¥29.48 | 1693.87 |
| 2025-06-04 | 国药现代(600420.SH) | 买 | 1200 | 10.9 | 13080 | ¥5 | 0 |
| 2025-06-04 | 亚宝药业(600351.SH) | 买 | 2100 | 6.26 | 13146 | ¥5 | 0 |
| 2025-05-30 | 亚宝药业(600351.SH) | 买 | 3630 | 6.04 | -4.8 | ¥0 | 0 |
| 2025-05-27 | 国药现代(600420.SH) | 买 | 100 | 10.35 | 1035 | ¥5 | 0 |
| 2025-05-27 | 亚宝药业(600351.SH) | 卖 | -600 | 6.26 | -3756 | ¥8.76 | 82.91 |
| 2025-05-20 | 亚宝药业(600351.SH) | 卖 | -200 | 6.22 | -1244 | ¥6.24 | 19.64 |
| 2025-05-13 | 亚宝药业(600351.SH) | 买 | 500 | 6.11 | 3055 | ¥5 | 0 |
| 2025-05-06 | 千红制药(002550.SZ) | 卖 | -74500 | 6.11 | -455195 | ¥591.75 | 4334.78 |
| 2025-05-06 | 九安医疗(002432.SZ) | 卖 | -11900 | 37.81 | -449939 | ¥584.92 | -81055.34 |
